medpace holdings inc - MEDP

MEDP

Close Chg Chg %
501.50 -7.97 -1.59%

Closed Market

493.53

-7.97 (1.59%)

Volume: 192.11K

Last Updated:

Apr 10, 2026, 4:00 PM EDT

Company Overview: medpace holdings inc - MEDP

MEDP Key Data

Open

$503.10

Day Range

487.86 - 503.10

52 Week Range

250.05 - 628.92

Market Cap

$14.32B

Shares Outstanding

28.56M

Public Float

22.94M

Beta

1.39

Rev. Per Employee

N/A

P/E Ratio

32.82

EPS

$15.65

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

315.47K

 

MEDP Performance

1 Week
 
0.63%
 
1 Month
 
11.34%
 
3 Months
 
-15.71%
 
1 Year
 
68.45%
 
5 Years
 
190.39%
 

MEDP Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 13
Full Ratings ➔

About medpace holdings inc - MEDP

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The firm's services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. It operates through the following geographical segments: United States, Europe, Belgium, Asia-Pacific, and Other. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

MEDP At a Glance

Medpace Holdings, Inc.
5375 Medpace Way
Cincinnati, Ohio 45227
Phone 1-513-579-9911 Revenue 2.53B
Industry Miscellaneous Commercial Services Net Income 451.12M
Sector Commercial Services 2025 Sales Growth 19.97%
Fiscal Year-end 12 / 2026 Employees 6,200
View SEC Filings

MEDP Valuation

P/E Current 32.824
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 36.761
Price to Sales Ratio 6.554
Price to Book Ratio 34.625
Price to Cash Flow Ratio 23.25
Enterprise Value to EBITDA 28.813
Enterprise Value to Sales 6.412
Total Debt to Enterprise Value 0.008

MEDP Efficiency

Revenue/Employee 408,102.258
Income Per Employee 72,761.774
Receivables Turnover 6.293
Total Asset Turnover 1.241

MEDP Liquidity

Current Ratio 0.736
Quick Ratio 0.736
Cash Ratio 0.37

MEDP Profitability

Gross Margin 28.95
Operating Margin 21.142
Pretax Margin 21.436
Net Margin 17.829
Return on Assets 22.134
Return on Equity 70.235
Return on Total Capital 75.702
Return on Invested Capital 59.183

MEDP Capital Structure

Total Debt to Total Equity 29.811
Total Debt to Total Capital 22.965
Total Debt to Total Assets 6.928
Long-Term Debt to Equity 24.755
Long-Term Debt to Total Capital 19.07
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Medpace Holdings Inc - MEDP

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.46B 1.89B 2.11B 2.53B
Sales Growth
+27.80% +29.17% +11.84% +19.97%
Cost of Goods Sold (COGS) incl D&A
1.05B 1.39B 1.48B 1.80B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
40.36M 26.33M 29.25M 28.12M
Depreciation
37.00M 24.13M 27.81M 27.18M
Amortization of Intangibles
3.35M 2.20M 1.44M 946.00K
COGS Growth
+25.69% +32.17% +6.80% +21.30%
Gross Income
410.10M 498.18M 627.05M 732.49M
Gross Income Growth
+33.57% +21.48% +25.87% +16.82%
Gross Profit Margin
+28.09% +26.42% +29.73% +28.95%
2022 2023 2024 2025 5-year trend
SG&A Expense
131.40M 161.35M 180.18M 197.56M
Research & Development
- - - -
-
Other SG&A
131.40M 161.35M 180.18M 197.56M
SGA Growth
+21.19% +22.79% +11.67% +9.64%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
278.70M 336.82M 446.87M 534.93M
Non Operating Income/Expense
7.07M (655.00K) 29.05M 7.44M
Non-Operating Interest Income
- - - 25.00M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 2.90M 488.00K
-
Interest Expense Growth
- - +2,666.67% -83.20%
-
Gross Interest Expense
- - 2.90M 488.00K
-
Interest Capitalized
- - - -
-
Pretax Income
282.86M 335.68M 475.92M 542.38M
Pretax Income Growth
+40.13% +18.67% +41.78% +13.96%
Pretax Margin
+19.37% +17.80% +22.57% +21.44%
Income Tax
37.49M 52.87M 71.54M 91.25M
Income Tax - Current - Domestic
57.15M 73.23M 92.28M 2.29M
Income Tax - Current - Foreign
3.33M 4.62M 5.88M 8.05M
Income Tax - Deferred - Domestic
(23.00M) (25.99M) (25.54M) 82.05M
Income Tax - Deferred - Foreign
13.00K 1.01M (1.08M) (1.13M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- (157.00K) (191.00K) (44.00K)
Consolidated Net Income
245.21M 282.62M 404.34M 451.12M
Minority Interest Expense
- - - -
-
Net Income
245.21M 282.62M 404.34M 451.12M
Net Income Growth
+35.18% +15.26% +43.07% +11.57%
Net Margin Growth
+16.80% +14.99% +19.17% +17.83%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
245.21M 282.62M 404.34M 451.12M
Preferred Dividends
- - - -
-
Net Income Available to Common
245.21M 282.62M 404.34M 451.12M
EPS (Basic)
7.571 9.1992 13.0614 15.639
EPS (Basic) Growth
+49.68% +21.51% +41.98% +19.73%
Basic Shares Outstanding
32.39M 30.72M 30.96M 28.85M
EPS (Diluted)
7.2826 8.876 12.6302 15.2783
EPS (Diluted) Growth
+51.35% +21.88% +42.30% +20.97%
Diluted Shares Outstanding
33.67M 31.84M 32.01M 29.53M
EBITDA
319.05M 363.15M 476.12M 563.06M
EBITDA Growth
+35.18% +13.82% +31.11% +18.26%
EBITDA Margin
+21.85% +19.26% +22.58% +22.25%

Snapshot

Average Recommendation HOLD Average Target Price 512.00
Number of Ratings 13 Current Quarters Estimate 4.077
FY Report Date 06 / 2026 Current Year's Estimate 17.15
Last Quarter’s Earnings 3.92 Median PE on CY Estimate N/A
Year Ago Earnings 15.28 Next Fiscal Year Estimate 19.07
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 11 11
Mean Estimate 4.08 4.41 17.15 19.07
High Estimates 4.26 4.62 17.45 19.81
Low Estimate 3.70 4.28 16.96 18.47
Coefficient of Variance 4.31 2.27 0.85 1.93

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 1
OVERWEIGHT 1 1 0
HOLD 8 9 9
UNDERWEIGHT 0 1 1
SELL 1 1 4
MEAN Hold Hold Hold

Insider Actions for Medpace Holdings Inc - MEDP

Date Name Shares Transaction Value
Nov 21, 2025 August James Troendle CEO; Director 886,177 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $590.84 per share 523,588,818.68
Nov 21, 2025 August James Troendle CEO; Director 862,315 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $592.07 per share 510,550,842.05
Jul 29, 2025 Jesse J. Geiger President 78,304 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $107.93 per share 8,451,350.72
Jul 29, 2025 Jesse J. Geiger President 36,503 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $453.11 per share 16,539,874.33
Jul 29, 2025 Jesse J. Geiger President N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 29, 2025 Kevin M. Brady CFO & Treasurer 18,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $57.94 per share 1,042,920.00
Jul 29, 2025 Kevin M. Brady CFO & Treasurer 6,000 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $454.23 per share 2,725,380.00
Jul 29, 2025 Kevin M. Brady CFO & Treasurer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 21, 2025 Fred B. Davenport Director 1,224 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Cornelius P. McCarthy Director 1,224 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Robert O. Kraft Director 1,224 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Brian T. Carley Director 1,224 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Femida H. Gwadry-Sridhar Director 1,224 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 21, 2025 Dani S. Zander Director 1,224 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Medpace Holdings Inc in the News